As of 2026, there is no approved cure for long COVID, and no single long COVID treatment has been proven to work for everyone. What exists is a growing body of research: large national programs and clinical trials are studying repurposed drugs, immune-focused approaches, and rehabilitation strategies. This article reviews what is being studied. It is informational only and not medical advice.
Key takeaways
- No treatment is currently approved to cure long COVID; the approaches below are being studied, not proven.
- Research includes the NIH RECOVER initiative, antiviral and immune-modulating candidates, and low-dose naltrexone, among others.
- Clinical management today generally focuses on treating specific symptoms and pacing, guided by a clinician.
- This post does not recommend any treatment or dose. Decisions about any therapy belong with your own doctor.
- Some people track inflammation markers such as IL-6, TNF, and CRP around any change, as objective context to discuss with their clinician.
What long COVID treatments are being researched in 2026?
Long COVID research spans several directions at once, reflecting the different mechanisms scientists are investigating. Areas under active study include:
- Antiviral strategies: trials examining whether targeting persistent virus or viral remnants changes symptoms.
- Immune-modulating approaches: candidates aimed at the abnormal immune signaling reported in some long COVID studies.
- Autonomic and cardiovascular approaches: studies focused on symptoms like a racing heart or lightheadedness on standing.
- Rehabilitation and pacing: structured approaches designed around post-exertional malaise, where over-exertion can worsen symptoms.
Each of these is a research question, not a settled answer. Results so far are mixed or preliminary, and what looks promising in one trial may not hold up in another.
What is the NIH RECOVER initiative studying?
RECOVER is a large research program funded by the U.S. National Institutes of Health to understand, prevent, and treat long COVID. It combines observational studies that track thousands of people over time with clinical trials that test specific interventions across the illness's many presentations, including fatigue, cognitive symptoms, sleep problems, and autonomic dysfunction. The value of a program this size is that it studies interventions rigorously rather than relying on anecdote. Its trials are ongoing, and their purpose is to find out what helps, which means no conclusion should be assumed in advance.
Are repurposed drugs and low-dose naltrexone being studied for long COVID?
Yes. A recurring theme in long COVID research is repurposing: testing existing, already-approved medicines to see whether they help with long COVID symptoms. Low-dose naltrexone (LDN) is one example that has drawn attention and is being studied for symptoms such as fatigue and pain, though the evidence remains limited and it is not proven for long COVID. Other repurposed candidates from antiviral, anti-inflammatory, and cardiovascular categories are also under investigation.
It is important to be clear: mentioning that something is being studied is not a recommendation, and this article gives no dosing information. If you are curious about LDN specifically, our note on what to track with low-dose naltrexone for long COVID focuses on measurement, and any decision about trying it should be made with your doctor.
How is long COVID managed while research continues?
Because no cure is approved, current clinical care generally centers on managing individual symptoms and supporting function. That can include pacing to avoid post-exertional crashes, addressing sleep, and treating specific problems such as orthostatic symptoms, always under a clinician's guidance and tailored to the person. This is symptom management, not a proven disease-modifying treatment, and approaches differ from patient to patient.
How can you track inflammation markers around a change in your regimen?
If you and your doctor decide to try something, objective tracking can help you interpret what happens rather than relying on how you feel on a given day. Some people monitor inflammation-signaling molecules because research has associated persistent long COVID with differences in immune signaling. Markers people commonly follow include IL-6, TNF, and CRP, watching whether they move relative to a healthy reference range across time points. Muno Mirror measures a 250-plex inflammation proteomics panel from a small at-home microsample and benchmarks each marker against a healthy reference, and it supports retesting so you can compare before and after. This is measurement for informational use, to interpret with your doctor. It is not a treatment, and it does not diagnose long COVID or any disease. You can see what Muno Mirror measures, and our guide on telling whether a long COVID intervention is working explains how to structure baseline and retest around any change.
Frequently asked questions
Is there a cure for long COVID in 2026?
No. As of 2026 there is no approved cure for long COVID. Multiple treatments are being studied in clinical trials, but none has been proven to work for everyone. Care today focuses on managing symptoms with a clinician. Talk to your doctor about your options.
What long COVID clinical trials are underway?
Research programs including the NIH RECOVER initiative are running trials on antiviral, immune-modulating, autonomic, and rehabilitation approaches, along with repurposed medicines. These studies are ongoing and their outcomes are not yet settled. Being enrolled in or aware of a trial is something to discuss with your doctor.
Does low-dose naltrexone work for long COVID?
It is being studied for symptoms like fatigue and pain, but it is not proven for long COVID and the evidence is limited. This article does not recommend it or provide dosing. Any decision about low-dose naltrexone should be made with your doctor.
Should I track inflammation markers if I try a long COVID treatment?
Some people choose to track markers such as IL-6, TNF, and CRP around a change for objective context, then review the numbers with their clinician. This is informational monitoring, not a treatment or a diagnosis, and it does not tell you whether a therapy works on its own.